DOP2024000234A - Agentes aglutinantes 5t4 y usos de los mismos - Google Patents

Agentes aglutinantes 5t4 y usos de los mismos

Info

Publication number
DOP2024000234A
DOP2024000234A DO2024000234A DO2024000234A DOP2024000234A DO P2024000234 A DOP2024000234 A DO P2024000234A DO 2024000234 A DO2024000234 A DO 2024000234A DO 2024000234 A DO2024000234 A DO 2024000234A DO P2024000234 A DOP2024000234 A DO P2024000234A
Authority
DO
Dominican Republic
Prior art keywords
binding agents
antibodies
antibody
present disclosure
disclosure provides
Prior art date
Application number
DO2024000234A
Other languages
English (en)
Spanish (es)
Inventor
Kantak Seema
Hammer Bonnie
N Higaki Jeffrey
Kaplan Charles
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of DOP2024000234A publication Critical patent/DOP2024000234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DO2024000234A 2022-05-13 2024-11-11 Agentes aglutinantes 5t4 y usos de los mismos DOP2024000234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263341944P 2022-05-13 2022-05-13
PCT/US2023/066819 WO2023220626A2 (en) 2022-05-13 2023-05-10 5t4 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
DOP2024000234A true DOP2024000234A (es) 2025-02-28

Family

ID=88731098

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2024000234A DOP2024000234A (es) 2022-05-13 2024-11-11 Agentes aglutinantes 5t4 y usos de los mismos

Country Status (16)

Country Link
US (1) US20250326858A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522660A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025518493A (cg-RX-API-DMAC7.html)
KR (1) KR20250024530A (cg-RX-API-DMAC7.html)
CN (2) CN119546643A (cg-RX-API-DMAC7.html)
AU (1) AU2023267764A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252305A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024003442A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015383A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240489A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000234A (cg-RX-API-DMAC7.html)
IL (1) IL316788A (cg-RX-API-DMAC7.html)
MX (1) MX2024013871A (cg-RX-API-DMAC7.html)
PE (1) PE20251275A1 (cg-RX-API-DMAC7.html)
TW (1) TW202400639A (cg-RX-API-DMAC7.html)
WO (1) WO2023220626A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180472A1 (zh) * 2024-02-28 2025-09-04 惠和生物技术(上海)有限公司 单克隆抗体分子及其用途
WO2026010986A1 (en) * 2024-07-05 2026-01-08 Solve Therapeutics, Inc. 5t4-binding proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170091A1 (en) * 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
WO2016034666A1 (en) * 2014-09-04 2016-03-10 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
KR20220030934A (ko) * 2019-05-31 2022-03-11 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 항-gal9 면역-억제 결합 분자

Also Published As

Publication number Publication date
PE20251275A1 (es) 2025-05-14
JP2025518493A (ja) 2025-06-17
EP4522660A4 (en) 2026-04-29
CN119546643A (zh) 2025-02-28
WO2023220626A2 (en) 2023-11-16
CL2025002572A1 (es) 2025-10-03
WO2023220626A3 (en) 2023-12-14
CA3252305A1 (en) 2023-11-16
KR20250024530A (ko) 2025-02-18
CN120607619A (zh) 2025-09-09
TW202400639A (zh) 2024-01-01
US20250326858A1 (en) 2025-10-23
MX2024013871A (es) 2024-12-06
EP4522660A2 (en) 2025-03-19
CL2024003442A1 (es) 2025-02-28
CO2024015383A2 (es) 2025-02-04
CR20240489A (es) 2025-01-07
AU2023267764A1 (en) 2024-11-21
IL316788A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
CO2024015383A2 (es) Agentes aglutinantes 5t4 y usos de los mismos
CL2024001473A1 (es) Conjugados de fármacos y anticuerpos anti-ccr7
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
CL2023003607A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
CL2021002242A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
PE20201464A1 (es) Conjugados anticuerpo anti-cd40-farmaco
MX374810B (es) Anticuerpos 4-1bb anti-humano y usos de los mismos
MX2022014125A (es) Anticuerpos y conjugados de los mismos.
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
MX381760B (es) Tintas cerca de infrarrojo (nir) dirigidas por antìgeno prostàtico especìfico de membrana (psma) y sus usos.
MX2022010515A (es) Conjugacion mediada por transglutaminasa.
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
BR112023014128A2 (pt) Conjugados de anticorpo-fármaco imunomodulatórios
MX2022006132A (es) Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
GT201100023A (es) Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos
AR104987A1 (es) Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
BR112017022252A2 (pt) conjugados de anticorpo-droga sítio-específicos
CO2024015381A2 (es) Conjugados anticuerpo-fármaco 5t4 y usos de los mismos
MX2023009146A (es) Anticuerpos y usos de estos.
UY37669A (es) Conjugados de fármaco-anticuerpo (adc) anti-prlr y usos de los mismos
CL2021002838A1 (es) Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo.
MX2024002720A (es) Nanocuerpos anti-4-1bb.
MX2024002407A (es) Anticuerpos y conjugados sirp-alfa.